Are you Dr. Chowdhury?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 38 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
6900 Georgia Ave., Pod 1j
Dept Of Allergy And Immunology, Wramc
Washington, DC 20307Phone+1 202-782-9461- Is this information wrong?
Summary
- Dr. Badrul Chowdhury, MD is an allergist/immunologist in Washington, District of Columbia. He is currently licensed to practice medicine in District of Columbia, Pennsylvania, and Tennessee.
Education & Training
- National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 1991 - 1994
- Wayne State University School of MedicineResidency, Internal Medicine, 1988 - 1991
- Dhaka Medical CollegeClass of 1982
Certifications & Licensure
- MD State Medical License 1989 - 2024
- DC State Medical License 1998 - 2022
- PA State Medical License 1998 - 2002
- MI State Medical License 1990 - 2000
- TN State Medical License 1995 - 1999
Publications & Presentations
PubMed
- 5 citationsA disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patientsYouwei Bi, Dinko Rekić, Miya O Paterniti, Jianmeng Chen, Anshu Marathe, Badrul A. Chowdhury, Banu A Karimi-Shah, Yaning Wang> ;Journal of Pharmacokinetics and Pharmacodynamics. 2021 Feb 1
- 12 citationsScientific Considerations for the Review and Approval of First Generic Mometasone Furoate Nasal Suspension Spray in the United States from the Bioequivalence PerspectiveQing Liu, Mohammad Absar, Bhawana Saluja, Changning Guo, Badrul A. Chowdhury, Robert Lionberger, Dale P. Conner, Bing V. Li> ;The AAPS Journal. 2019 Jan 7
- 9 citationsConsiderations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a DiseaseRobert N. Schuck, Janet Woodcock, Issam Zineh, Peter Stein, Jonathan P. Jarow, Robert Temple, Thomas Permutt, Lisa M. LaVange, Julia A. Beaver, Rosane Charlab, Gideon ...> ;Clinical Pharmacology and Therapeutics. 2018 Aug 1
- Join now to see all
Press Mentions
- Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) TrialJune 30th, 2021
- Savara Reports First Quarter 2021 Financial Results and Provides Business UpdateMay 13th, 2021
- Savara Provides Pipeline and Business UpdateDecember 10th, 2020
- Join now to see all